Out in open

The more, the merrier. Join and conjoin!

Friday, June 22, 2007

The Side Effects of Celebrex

The Side Effects of Celebrex

            For the most part, anti-inflammatory drugs cause more than 16,000 deaths (including 100,000 hospitalizations annually).  According to the Physicians' Desk Reference "serious gastrointestinal toxicity such as bleeding, ulceration, and perforation, can occur at any time.  This can happen with or without warning symptoms, in patients treated chronically with non-steroidal anti-inflammatory drugs."  More specifically, the most common side effects of C! elebrex are nausea, diarrhea and heartburn (in addition to upset stomach and stomach pain).  In rare cases, Celebrex can also cause stomach ulcers or stomach bleeding.  However, patients who use the lowest effective dose—for only as long as they are experiencing pain—may lower their risk of these side effects.  

Wednesday, June 20, 2007

Where to find legal advice

If you arrive to this page looking for claims, lawsuits, settlements or require the services of a competent celebrex attorney just check the links to find what you need. More information on Celebrex coming soon.  

The History of Celebrex

The History of Celebrex

            Pfizer began marketing its drug Celecoxib, under the brand name of Celebrex, in 1999 (note: in some countries the drug is also branded as Celebra).  Celebrex is a non-steroidal anti-inflammatory drug (NSAID).&nbs! p; From a molecular standpoint, Celebrex is a highly selective COX-2 inhibitor.  Specifically, it inhibits cyclooxygenase (the production of prostaglandin).  It is differentiated from other NSAIDs in that, unlike Celebrex, they inhibit both COX-1 and COX-2.  Celebrex is primarily used and licensed to treat rheumatoid arthritis, osteoarthritis and acute pain.  However, it's also both licensed and prescribed to treat the pain associated with menstruation (and various other menstrual issues).  Celebrex has also been used to reduce the amount of colon and rectum polyps, occurring in patients diagnosed with adenomatous polyposis.